Halaman 1 dari 94 hasil
BACKGROUND OF THE INVENTION
The present invention relates generally to methods and reagents used in the detection of cancer. More particularly, the present invention relates to a new diagnostic approach for the detection of chronic myelogenous leukemia.
Leukemia is a malignant disease of the
BACKGROUND
Hyperproliferative disorders, such as cancer, are associated with the growth of abnormal, or neoplastic cells. In cancer, this uncontrolled cellular proliferation will often result in unregulated growth of malignant tissue and invasion of adjacent or local cells. Eventually, the malignant
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to Indian Patent Application No. 201711030707, filed Aug. 30, 2017, the entirety of which is incorporated herein by reference.
REFERENCE TO SEQUENCE LISTING
Applicants assert that the paper copy of the Sequence Listing is
RELATED APPLICATIONS
This application claims the benefit of, and priority to, PCT serial number PCT/US06/034050, filed Aug. 31, 2006, presently pending, the disclosure of which is incorporated herein, in its entirety, by reference.
FIELD OF THE INVENTION
The invention relates generally to antibodies
FIELD OF THE INVENTION
The present invention relates to methods for treating leukemia, and more particularly, to the use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia.
BACKGROUND OF THE INVENTION
Leukemia is a malignant cancer of the bone marrow and
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
FIELD OF THE INVENTION
This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable.
THE NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT
Not Applicable
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC
Not Applicable
BACKGROUND OF THE INVENTION
(1) Field of the Invention
(2) Description
BACKGROUND OF THE INVENTION
Chronic myelogenous leukemia (CML) is a disease having clinical and pathological features distinct from those of other forms of leukemia. It is widely accepted that the cause of CML is a specific chromosomal translocation between human chromosome 9 and human chromosome
The invention relates to a method of treating a warm-blooded animal, especially a human, having leukaemia comprising administering to the animal at least one compound inhibiting the c-Src protein tyrosine kinase activity, especially those compounds mentioned herein, in a quantity which is effective
The invention relates to a method of treating a warm-blooded animal, especially a human, having leukaemia comprising administering to the animal at least one compound inhibiting the c-Src protein tyrosine kinase activity, especially those compounds mentioned herein, in a quantity which is effective
FIELD OF THE INVENTION
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]- -benzamide, that inhibits the T315I mutation in
This invention relates to compounds. More specifically, the invention relates to compounds useful as kinase inhibitors, along with processes to prepare the compounds and uses of the compounds. Specifically, the invention relates to inhibitors of Bruton's tyrosine kinase (BTK).
BACKGROUND
Kinases are
RELATED APPLICATIONS
This application is a national phase filing under 35 U.S.C. 371 of International Application No. PCT/GB2015/051719, filed Jun. 11, 2015, which claims the benefit of and priority to United Kingdom Patent Application No. GB1410430.1, filed Jun. 11, 2014, the contents of which
This application is a national stage entry under 35 USC .sctn.371 of PCT/EP02/12076, filed Oct. 29, 2002, which claims benefit of Provisional Application No. 60/339,031 filed Oct. 30, 2001, and Provisional Application No. 60/338,185 filed Dec. 7, 2001, each of which is here incorporated by reference